Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 13/20 | 0.65 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.65 |
| ▸ | PARP11 | Q9NR21 | 7/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15474121 | 0.85 | PARP1 (0.58) | PARP1PARP10PARP11PDPK1MRGPRX4 | |
| SCHEMBL22469818 | 0.85 | PARP1 (0.63) | PARP1PARP10PARP11PDPK1MRGPRX4 | |
| SCHEMBL30197573 | 0.85 | PARP1 (0.63) | PARP1PARP10PARP11PDPK1MRGPRX4 | |
| SCHEMBL20627541 | 0.84 | PARP1 (0.58) | PARP1PARP10PARP11PDPK1MRGPRX4 | |
| SCHEMBL12219092 | 0.82 | CDK5 (0.58) | PARP1PARP10PARP11 | |
| SCHEMBL29687894 | 0.79 | PARP1 (1.00) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL831538 | 0.79 | PARP1 (1.00) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL7581574 | 0.78 | PARP1 (0.58) | PARP1PARP10PARP11PDPK1MRGPRX4 | |
| SCHEMBL26162802 | 0.77 | PARP10 (0.56) | PARP1PARP10PARP11PDPK1MRGPRX4 | |
| SCHEMBL5542232 | 0.77 | NOTUM (0.44) | PARP1PARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | claimed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | claimed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | claimed |
| US-11325930-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210147454-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210061831-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2021-03-04 | — | — | US | disclosed |
| US-6348475-B1 | POLYMERASE INHIBITOR | GUILFORD PHARMACEUTICALS INC. | 2002-02-19 | — | — | US | disclosed |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | EISAI INC. | 2002-02-14 | — | — | US | disclosed |
| EP-0669912-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325930-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | PARP1 1381/4885PARP10 1538/4885PARP11 1402/4885 |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | PARP2, PARP1, PARP3 | PARP1 2/4885PARP10 15/4885PARP11 7/4885 |
| US-20210147454-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | PARP1 1381/4885PARP10 1538/4885PARP11 1402/4885 |
| US-20210061831-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | PARP1 1381/4885PARP10 1538/4885PARP11 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.